Concepedia

Christine E. Horak

CE

Statistics

Publications

64

Citations

35.3K

H-Index

42

Active since

1999

Affiliations

Bristol-Myers Squibb (United States)(Current)

Dana-Farber Cancer Institute

Memorial Sloan Kettering Cancer Center

Cornell University

Yale University

Christine E. Horak is an author at Bristol-Myers Squibb (United States) specializing in oncology, cancer immunotherapy, and immunotherapy.

Publications per year

1999–2023

64

Publications

64

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

James Larkin, Vanna Chiarion‐Sileni, René González et al. · New England Journal of Medicine · 2015 · 8.1K citations · Full text

Life Sciences, Oncology, Pharmacotherapy +17

Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation

Caroline Robert, Georgina V. Long, Benjamin Brady et al. · New England Journal of Medicine · 2014 · 5.4K citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Nivolumab plus Ipilimumab in Advanced Melanoma

Jedd D. Wolchok, Harriet M. Kluger, Margaret K. Callahan et al. · New England Journal of Medicine · 2013 · 4.2K citations · Full text

Medicine, Oncology, Pharmacology +17

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

Michael A. Postow, Jason Chesney, Anna C. Pavlick et al. · New England Journal of Medicine · 2015 · 2.8K citations · Full text

Life Sciences, Immunology, Oncology +17

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

Jeffrey S. Weber, Sandra P. D’Angelo, David R. Minor et al. · The Lancet Oncology · 2015 · 2.7K citations

Medicine, Oncology, Pharmacotherapy +16

1–5 of 64